You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

ERBITUX Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for ERBITUX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of MiamiPhase 1/Phase 2
BioMed Valley Discoveries, IncPhase 1
Jonathan RiessPhase 1

See all ERBITUX clinical trials

Recent Litigation for ERBITUX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd.2023-10-20
Janssen Biotech, Inc. v. Amgen Inc.2022-11-29
Ravgen, Inc. v. Quest Diagnostics Incorporated2021-11-17

See all ERBITUX litigation

PTAB Litigation
PetitionerDate
Illumina, Inc. et al.2021-07-20
Laboratory Corporation of America Holdings et al.2021-05-28
Quest Diagnostics Incorporated2021-04-15

See all ERBITUX litigation

Pharmacology for ERBITUX
Mechanism of ActionHER1 Antagonists
Established Pharmacologic ClassEpidermal Growth Factor Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ERBITUX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ERBITUX Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Eli Lilly And Company ERBITUX cetuximab Injection 125084 ⤷  Try for Free 2018-04-17 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for ERBITUX Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for ERBITUX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122008000027 Germany ⤷  Try for Free PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
08C0022 France ⤷  Try for Free PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001 20071203
91448 Luxembourg ⤷  Try for Free 91448, EXPIRES: 20140915
122008000028 Germany ⤷  Try for Free PRODUCT NAME: PANITUMUMAB MIT EINEM ANTINEOPLASTISCHEN WIRKSTOFF, INSBESONDERE PANITUMUMAB MIT EINEM ODER MEHREREN DER FOLGENDEN 1 BIS 22: 1 IRINOTECAN 2 CISPLATIN 3 5-FLUORURACIL 4 FOLINSAEURE 5 CISPNSAEURE, 5-FLUORURACIL UND IRINOTECAN =FOLFIRI 9 FOLINSAEURE, 5-FLUORURACIL UND OXALI; REGISTRATION LATIN UND/ODER DOCETAXEL 6 OXALIPLATIN UND/ODER CAPECITABIN 7 IRINOTECAN UND/ODER CYCLOSPORIN 8 FOLINO/DATE: EU/1/07/423/001-003 20071203
91449 Luxembourg ⤷  Try for Free 91449, EXPIRES: 20140915
122004000041 Germany ⤷  Try for Free PRODUCT NAME: CETUXIMAB; REGISTRATION NO/DATE: EU/1/04/281/001 20040629
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Biologic Drug: Erbitux

Introduction

Erbitux, a biologic drug containing the active substance cetuximab, is used primarily for the treatment of metastatic colorectal cancer and head and neck cancer. Here, we delve into the market dynamics and financial trajectory of Erbitux, highlighting key drivers, restraints, opportunities, and regional market analyses.

Market Growth and Forecast

The global Erbitux market is projected to experience significant growth, with a Compound Annual Growth Rate (CAGR) of 15% from 2021 to 2027. This growth is anticipated to take the market size from over USD 1 billion in 2021 to around USD 3 billion by 2027[3][5].

Drivers of Market Growth

Several factors are driving the growth of the Erbitux market:

  • Increasing Demand for Cancer Treatment: The growing demand for treatments of metastatic colorectal cancer and head and neck cancer is a major driver. These cancers are prevalent, with over 880,000 estimated new cases of head and neck cancers worldwide each year, particularly in the Asia-Pacific region[3][5].
  • Advancements in Healthcare: Improvements in healthcare infrastructure and the increasing availability of advanced cancer treatments are also contributing to market growth.
  • Presence of Key Market Players: Major pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Eli Lilly are actively involved in the market, driving innovation and accessibility[5].

Restraints

Despite the positive growth trajectory, there are several restraints that could impact the market:

  • Side Effects: Severe allergic reactions and other side effects associated with Erbitux are expected to hamper market growth. These adverse effects can deter some patients from opting for this treatment[1][5].
  • High Development and Approval Costs: Although biologic drugs like Erbitux have lower capitalized development and approval costs compared to some other drug categories, the overall costs are still significant. This can be a barrier for new entrants and may affect pricing strategies[2].

Opportunities

The Erbitux market presents several opportunities for growth and expansion:

  • Development of Biosimilars: The upcoming development of biosimilars is expected to offer new opportunities globally. Biosimilars can provide cost-effective alternatives, increasing access to treatment and potentially expanding the market[1][3][5].
  • Emerging Markets: The Asia-Pacific region, in particular, is anticipated to grow at the highest rate due to the high incidence of head and neck cancers and improving healthcare infrastructure[3].

Regional Market Analysis

The global Erbitux market is segmented into several key regions:

  • North America: This region currently holds the largest share in the global Erbitux market, driven by the high prevalence of colorectal cancer and the presence of major pharmaceutical companies[3][5].
  • Europe: Europe is another significant market, with a well-established healthcare system and a high demand for advanced cancer treatments.
  • Asia-Pacific: This region is expected to grow at the highest rate due to the increasing number of cancer cases and improving healthcare facilities[3].
  • Rest of the World (RoW): Other regions, including Latin America, Africa, and the Middle East, also present opportunities for growth, although at a slower pace compared to the other regions[1][5].

Market Segmentation

The Erbitux market is segmented based on types, applications, and end users:

  • Types: The market includes 100 mg/50 ml and 200 mg/100 ml injections[5].
  • Applications: The primary applications are in the treatment of head and neck cancer and metastatic colorectal cancer[3][5].
  • End Users: The market is segmented into hospital pharmacies, retail pharmacies, and other categories[1][5].

Competitive Landscape

The competitive landscape of the Erbitux market is characterized by the presence of several key players:

  • Merck: As the primary manufacturer, Merck plays a significant role in the market.
  • Bristol-Myers Squibb: Another major player, Bristol-Myers Squibb, contributes to the market through its extensive product portfolio and research capabilities.
  • Eli Lilly: Eli Lilly is also a key player, with a strong presence in the biologic drug market[5].

Financial Implications

The financial trajectory of Erbitux is influenced by several factors:

  • Revenue Growth: The market is expected to grow significantly, reaching USD 3 billion by 2027, driven by increasing demand and the development of biosimilars[3].
  • Cost Savings: The development and approval costs for biologic drugs like Erbitux, although high, are lower compared to some other drug categories. This can lead to cost savings and more competitive pricing[2].
  • Pricing Strategies: The entry of biosimilars is expected to introduce price competition, with discounts ranging from 10 to 30% compared to the pioneer product. This can lead to expanded market access and greater consumer savings[4].

Porter's Five Forces Analysis

Porter's five forces model provides insights into the competitive dynamics of the Erbitux market:

  • Competitive Rivalry: The market is characterized by moderate to high competitive rivalry, with several key players competing for market share.
  • Supplier Power: Suppliers have moderate power due to the specialized nature of biologic drugs.
  • Buyer Power: Buyers have moderate power, influenced by the availability of biosimilars and the need for effective cancer treatments.
  • Threat of New Entrants: The threat of new entrants is moderate due to high development and approval costs, but the potential for biosimilars offers opportunities for new players.
  • Threat of Substitutes: The threat of substitutes is low due to the specific indications and efficacy of Erbitux[1][5].

Growth Matrix

The Growth Matrix in the reports highlights the investment areas that market players should focus on:

  • Product Segments: Market players should invest in the development of biosimilars and expand their product portfolios to include different types and applications.
  • Geographies: Focus on regions like the Asia-Pacific, where the demand for cancer treatments is high and growing[1][5].
"The development of biosimilars in the coming years will offer new opportunities in different parts of the world"[1].

Key Takeaways

  • The global Erbitux market is projected to grow at a CAGR of 15% from 2021 to 2027.
  • The market is driven by the growing demand for treatments of metastatic colorectal cancer and head and neck cancer.
  • Side effects and high development costs are significant restraints.
  • The development of biosimilars presents new opportunities.
  • North America currently holds the largest market share, but the Asia-Pacific region is expected to grow at the highest rate.
  • Key players include Merck, Bristol-Myers Squibb, and Eli Lilly.

FAQs

What is Erbitux used for?

Erbitux is used primarily for the treatment of metastatic colorectal cancer and head and neck cancer.

What is the projected growth rate of the Erbitux market?

The global Erbitux market is projected to grow at a CAGR of 15% from 2021 to 2027.

What are the main drivers of the Erbitux market?

The main drivers include the growing demand for cancer treatments, advancements in healthcare, and the presence of key market players.

What are the potential restraints for the Erbitux market?

The side effects of the drug, such as severe allergic reactions, and high development and approval costs are significant restraints.

How will the development of biosimilars impact the Erbitux market?

The development of biosimilars will offer new opportunities, increase market access, and introduce price competition, leading to greater consumer savings.

Sources

  1. ResearchAndMarkets.com: Erbitux Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027.
  2. ASPE: Antimicrobial Drugs Market Returns Analysis.
  3. Infinium Global Research: Erbitux Market Size, Share, Trends, Analysis, Industry Report 2027.
  4. Federal Trade Commission: Emerging Health Care Issues: Follow-on Biologic Drug Competition.
  5. BusinessWire: Erbitux Market Research Report 2022: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.